Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Spinocerebellar ataxia-dysmorphism is marked by characteristic facies associated with dysarthria, delayed psychomotor development, ataxia, scoliosis and foot deformities. Three cases have been described and transmission appears to be autosomal recessive.
Biomarker and diagnostic research for spinocerebellar ataxia-dysmorphism syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for spinocerebellar ataxia-dysmorphism syndrome.
136 publications have been identified in PubMed for spinocerebellar ataxia-dysmorphism syndrome. Research spans Case Report / Case Series (25%), Review / Meta-Analysis (21%), and Basic Science / Preclinical (19%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 34 | 25% |
Data assembled from 4 of 12 sources · Last updated Sep 17, 2026, 10:07 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries
29 |
21% |
Laboratory research | 26 | 19% |
Testing and diagnosis research | 18 | 13% |
Disease patterns and progression | 18 | 13% |
Clinical study results | 7 | 5% |
New treatment approaches | 3 | 2% |
Other research | 1 | 1% |
Bernardi E (2026). [PMID: 41596528](https://pubmed.ncbi.nlm.nih.gov/41596528/). *Int J Mol Sci*. [Review / Meta-Analysis]
Vieira AA (2026). [PMID: 41770293](https://pubmed.ncbi.nlm.nih.gov/41770293/). *Cerebellum*. [Gene Therapy / Novel Therapeutics]
Elias-Mas A (2026). [PMID: 41777701](https://pubmed.ncbi.nlm.nih.gov/41777701/). *Front Mol Neurosci*. [Basic Science / Preclinical]
Singh S (2026). [PMID: 41551727](https://pubmed.ncbi.nlm.nih.gov/41551727/). *NAR Mol Med*. [Basic Science / Preclinical]
Cardoso F (2026). [PMID: 41612618](https://pubmed.ncbi.nlm.nih.gov/41612618/). *Brain*. [Review / Meta-Analysis]
Matlawska M (2026). [PMID: 42096001](https://pubmed.ncbi.nlm.nih.gov/42096001/). *Cerebellum*. [Epidemiology / Natural History]
Khan N (2026). [PMID: 42051098](https://pubmed.ncbi.nlm.nih.gov/42051098/). *CNS Neurol Disord Drug Targets*. [Basic Science / Preclinical]
Fortin J (2026). [PMID: 41669957](https://pubmed.ncbi.nlm.nih.gov/41669957/). *Mov Disord*. [Epidemiology / Natural History]
Petit E (2026). [PMID: 41150672](https://pubmed.ncbi.nlm.nih.gov/41150672/). *Brain*. [Diagnostic / Biomarker]
Ramirez-Zamora A (2026). [PMID: 42261003](https://pubmed.ncbi.nlm.nih.gov/42261003/). *Mov Disord Clin Pract*. [Review / Meta-Analysis]